Eloxx Pharmaceuticals has finalized the design of its Phase 2 EXPRESS trial for exaluren, targeting nonsense mutation autosomal dominant polycystic kidney disease (ADPKD). The trial will enroll about 60 patients randomized to exaluren or placebo for 52 weeks, with kidney volume growth as the primary endpoint. The study aims to provide robust data for potential Breakthrough Therapy Designation and accelerated FDA approval. First dosing is expected in Q3 2027, with topline results anticipated in the first half of 2029. The company also appointed Dr. T.R. Srinivas as Chief Medical Officer to strengthen its clinical leadership.
Eloxx Pharmaceuticals' Phase 2 EXPRESS study design is the focus, with Pluang's Health sector data providing context. As of Oct 20, 2026 19:43 WIB, 89 of 150 Health-sector US stocks rose while 58 fell. Among notable movers, NUWE gained 5.52% with a strong 98% buy order activity and a typical hold time of 28 days, contrasting with ENVB which dropped 4.96% and saw 100% sell orders with a shorter hold time of 14 days.
SpaceX is set to report its Q3 2026 earnings with analysts expecting adjusted EPS of $0.13-$0.14 and revenue around $12.8 billion, a 64% increase year-over-year. Investors will closely watch Starlink's cash flow and the expanding AI infrastructure se...
RoyaLand Company Ltd. announced Palazzo Chronicles, a free-to-play mobile match-3 puzzle game set in 19th-century Piedmont during Italy's reunification. Players help Adelaide restore her inherited family castle by solving puzzles and rebuilding rooms...
Route 92 Medical has secured a $100 million senior secured debt facility from Trinity Capital to strengthen its balance sheet and support ongoing product innovation and commercial growth. The funding will help the company expand its neurovascular int...
American Electric Power (AEP) has a $147 price target from BTIG, implying a 17.9% upside from its current $124.72 price. The company is advancing a 960-megawatt nuclear project in Indiana with funding and power purchase support from Amazon, and a $4 ...
RBB Bancorp reported Q3 2026 earnings of $0.74 per share, surpassing the $0.58 estimate, and revenue of $36.87 million, a 13.2% increase year-over-year that beat forecasts. The bank improved key metrics including net interest margin rising to 3.16% a...
